Tag Archives: Novo Nordisk

Top Pharma News and Developments that Made Headlines in July

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Amgen signs collaboration agreement with Array BioPharma

2000px-amgen-svg

Amgen and Array BioPharma announced a preclinical license and collaboration agreement in inflammation.

Under the agreement, the two companies will collaborate on the discovery and development of new drugs for autoimmune disorders. Amgen will be responsible for clinical development and commercialization, having exclusive rights to Array’s preclinical program. In turn, upfront and milestone payments will be made by Amgen.

 

Bavarian Nordic partnered with Johnson & Johnson for HIV, HBV shots

j-j-logo

Danish company Bavarian Nordic and Johnson & Johnson have signed a deal worth USD 879M  to develop HIV, HBV shots.

Under the terms of the deal, Bavarian Nordic is granting J&J’s Janssen unit the rights to combine MVA-BN with Janssen’s own AdVac platform in the HIV and HBV programs. In return, Janssen will pay Bavarian Nordic $10 million upfront and up to $836 million in milestones. Bavarian Nordic will design, produce and deliver the MVA needed, while Janssen will handle R&D.

 

Samsung and Merck launched Remicade biosim

merck_logo

Samsung and Merck & Co. launched Renflexis in the US. Renflexis is 35% cheaper than J&J’s anti-inflammatory med.

Last year, Pfizer launched its version, Inflectra, at a 15% discount. Renflexis is the third biosim to launch in the US after Inflectra and Sandoz’s Zarxio, a biosimilar to Amgen’s Neupogen.

 

Gilead’s Vosevi got US FDA Approval

gilead

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.

The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies, which evaluated Vosevi during an interval of 12 weeks.

 

Novo Nordisk and Glooko launch co-marketed app

novo_nordisk-logo

As a result of Novo Nordisk’s partnership with diabetes health tech startup Glooko a new app was launched. It’s dubbed Cornerstones4Care Powered by Glooko, or the C4C app.

The app allows diabetes patients to measure and track blood glucose, activities and meals. It syncs blood glucose and activity data from a wide array of diabetes or exercise devices.

The app is free for registered C4C online users and can be downloaded from the Apple or Google app stores.

 

AstraZeneca partners with Merck to develop and commercialise cancer drugs

astrazeneca-svg

AstraZeneca and Merck & Co have entered a global oncology collaboration to co-develop and co-commercialise the AstraZeneca’s Lynparza and selumetinib for various cancer types.

Under the agreement, the companies will develop and commercialise Lynparza jointly, as monotherapy and in combination with other potential medicines. Furthermore, they will develop and commercialise Lynparza in combination with their own PD-L1 and PD-1 medicines, Imfinzi and Keytruda.

AstraZeneca and Merck will also co-develop and commercialise selumetinib, the former’s selective inhibitor of MEK, that’s being developed for several indications including thyroid cancer.

The 2 companies will share development and commercialisation costs as well as profits from product sales.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

 

Advertisements

February’s Top Pharma News & Developments

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

AstraZeneca entered agreement with TerSera Therapeutics for Zoladex

astrazeneca-svg

AstraZeneca entered an agreement with TerSera Therapeutics LLC for the commercial rights to Zoladex in the US and Canada. Zoladex is used to treat prostate cancer, breast cancer and several benign gynaecological disorders.

Under the agreement, TerSera is set to pay AstraZeneca USD 250 million upfront, plus USD 70 million in sales-related milestones and a quarterly share of sales in the “mid-teen percentage” range. AstraZeneca will also develop and supply Zoladex to TerSera.

 

Novo Nordisk filed for regulatory approval of semaglutide for the treatment of type 2 diabetes in Japan

novo_nordisk-logo

Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 analogue for the treatment of adults with type 2 diabetes.

This move follows the recent once-weekly semaglutide regulatory submissions to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada and SwissMedic.

 

Allergan Launched See America

allergan_logo_tm

Allergan launched a new initiative dubbed See America, through which it aims to make vision health a priority for all US residents. Increasing awareness of the diseases that can cause blindness and enhancing access to vision care for those who need it most are the initiative’s main focus.

The launch followed the release of a report published by the National Academies of Sciences, Engineering, and Medicine (NASEM), which stressed upon the overwhelming number of Americans affected by blindness from preventable causes.

 

Amgen’s Parsabiv got FDA approval

2000px-amgen-svg

The US Food and Drug Administration (FDA) approved Amgen’s Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.

Parsabiv is the first therapy approved for this condition in 12 years. It is also the only calcimimetic that can be administered intravenously three times a week after the hemodialysis session.

 

Roche to start second late-stage study of Alzheimer’s disease drug

roche

Roche’s partner AC Immune revealed that Roche is set to launch a second Phase III study of the experimental Alzheimer’s disease therapy crenezumab. The latter was discovered by AC Immune and out-licensed to Roche’s Genentech unit in 2006. The CREAD2 trial will enrol 750 patients with prodromal or mild Alzheimer’s disease.

 

Boehringer Ingelheim’s Giotrif got approved for lung cancer in China

boehringer_ingelheim_logo-svg

Global pharmaceutical company Boehringer Ingelheim announced that their afatinib (Giotrif), an irreversible second-generation ErbB family blocker, was approved for lung cancer in China.

Afatinib has received Imported Drugs License (IDL) status by the China Food and Drug Administration (CFDA) for locally advanced or metastatic EGFR mutation-positive lung cancer patients who have not received any prior therapy with tyrosine kinase inhibitors, as well as for patients with locally advanced or metastatic squamous cell carcinoma of the lung whose disease has progressed on or after treatment with platinum-based chemotherapy.

Afatinib is the first and only second-generation ErbB family blocker approved in China.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

  • EHA 2017 – 445 rooms in fourteen 4-star hotels
  • ESMO 2017 – 440 rooms in ten 4-star hotels
  • ESC 2017 – 150 rooms in five 4-star hotels
  • EURETINA 2017 – 160 rooms in five 4-star hotels
  • EASD 2017 – 423 rooms in thirteen 4-star hotels
  • EAACI 2017 – 688 rooms in fourteen 4-star hotels

January’s Top Pharma News & Developments

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Johnson & Johnson to acquire Actelion for USD 30 billion

j-j-logo

Johnson & Johnson is set to acquire Swiss biotech company Actelion. The deal is valued at USD 30 billion and will give J&J access to Actelion’s research and development pipeline, as well as medicines for rare diseases.

Under the agreement, Actelion will draw out its research and development unit into a standalone company dubbed R&D NewCo, based in Switzerland, and led by Actelion founder and CEO Jean-Paul Clozel.

J&J will initially hold a 16% stake in R&D NewCo, with rights to an additional 16%.

 

Sanofi, MSD ended vaccines JV

Impression

Sanofi Pasteur, the vaccines division of the multinational pharmaceutical company Sanofi, has ended its vaccines joint venture with MSD, a collaboration that spanned more than 20 years.

The move was first announced in March 2016 and the reason was that both companies wanted to pursue their “distinct growth strategies.”

Throughout its existence, Sanofi Pasteur MSD launched several vaccines onto the European market such as Gardasil and Zostavax.

 

Bristol-Myers Squibb entered clinical collaboration with Janssen

bms

Global biopharmaceutical company Bristol-Myers Squibb has entered a clinical research collaboration with US-based biotechnology company Janssen Biotech.

The aim of the collaboration is to analyse the combination of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase 1b/2 clinical studies in multiple myeloma and solid tumors.

In July 2016, Bristol-Myers Squibb and Janssen signed a clinical research collaboration to evaluate Opdivo and Live Attenuated Double-Deleted (LADD) Listerial monocytogenes cancer immunotherapy in patients with non-small cell lung cancer.

 

Merck teamed up with Palantir for faster drug discovery

merck_logo

German multinational pharma company Merck has teamed up with US-based data and analysis software company Palantir to enhance drug discovery and development.

In the beginning, the two companies will partner on three of Merck’s business sectors: healthcare, life sciences, and performance materials.

The exact terms of the deal haven’t yet been disclosed.

 

Novo Nordisk partnered Glooko to develop digital health solutions for patients with diabetes

novo_nordisk-logo

Health platform for diabetes management Glooko has teamed up with Danish multinational pharmaceutical company Novo Nordisk to develop and brand digital health solutions for people with diabetes.

Under the agreement, the companies are set to deliver personalised, digital services to support people with diabetes in what concerns treatment adherence and blood glucose management. The partnership will also make it easier for healthcare professionals to manage patients by leveraging data reporting.

Novo Nordisk’s Digital Health Platform was developed with IBM Watson Health and it aims to improve treatment outcomes.

 

Novartis in USD 1.6 bln deal with Ionis Pharmaceuticals

novartis

Novartis has entered an agreement with US-based biopharmaceutical company Ionis Pharmaceuticals.

Under the deal, Novartis will pay up to USD 1.6 billion to Ionis and its unit Akcea Therapeutics for the rights to two cardiovascular drugs that aim to lower the level of cholesterol-carrying proteins in the blood, thus reducing the risk of cardiovascular diseases. Furthermore, Novartis will invest USD 50 million in either Ionis or Akcea within the first 18 months, as well as payments worth up to USD 1.4 billion if the drugs turn out  successful.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are: